Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.25
XRAY's Cash to Debt is ranked lower than
86% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.46 vs. XRAY: 0.25 )
Ranked among companies with meaningful Cash to Debt only.
XRAY' s Cash to Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.16 Max: 0.96
Current: 0.25
0.03
0.96
Equity to Asset 0.70
XRAY's Equity to Asset is ranked higher than
69% of the 177 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. XRAY: 0.70 )
Ranked among companies with meaningful Equity to Asset only.
XRAY' s Equity to Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.52 Max: 0.7
Current: 0.7
0.34
0.7
Interest Coverage 15.90
XRAY's Interest Coverage is ranked lower than
76% of the 135 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 42.78 vs. XRAY: 15.90 )
Ranked among companies with meaningful Interest Coverage only.
XRAY' s Interest Coverage Range Over the Past 10 Years
Min: 6.71  Med: 10.6 Max: 32.95
Current: 15.9
6.71
32.95
F-Score: 6
Z-Score: 3.02
M-Score: -1.79
WACC vs ROIC
11.18%
5.53%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 12.14
XRAY's Operating margin (%) is ranked higher than
69% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.41 vs. XRAY: 12.14 )
Ranked among companies with meaningful Operating margin (%) only.
XRAY' s Operating margin (%) Range Over the Past 10 Years
Min: 11.85  Med: 14.73 Max: 17.66
Current: 12.14
11.85
17.66
Net-margin (%) 11.48
XRAY's Net-margin (%) is ranked higher than
75% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.23 vs. XRAY: 11.48 )
Ranked among companies with meaningful Net-margin (%) only.
XRAY' s Net-margin (%) Range Over the Past 10 Years
Min: 9.39  Med: 11.27 Max: 12.94
Current: 11.48
9.39
12.94
ROE (%) 6.06
XRAY's ROE (%) is ranked higher than
56% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.51 vs. XRAY: 6.06 )
Ranked among companies with meaningful ROE (%) only.
XRAY' s ROE (%) Range Over the Past 10 Years
Min: 6.06  Med: 13.89 Max: 18.61
Current: 6.06
6.06
18.61
ROA (%) 4.20
XRAY's ROA (%) is ranked higher than
60% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. XRAY: 4.20 )
Ranked among companies with meaningful ROA (%) only.
XRAY' s ROA (%) Range Over the Past 10 Years
Min: 4.2  Med: 6.55 Max: 10.69
Current: 4.2
4.2
10.69
ROC (Joel Greenblatt) (%) 33.16
XRAY's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.88 vs. XRAY: 33.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
XRAY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 31.15  Med: 38.16 Max: 54.55
Current: 33.16
31.15
54.55
Revenue Growth (3Y)(%) -6.00
XRAY's Revenue Growth (3Y)(%) is ranked lower than
72% of the 144 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.00 vs. XRAY: -6.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
XRAY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -6  Med: 7.9 Max: 21.5
Current: -6
-6
21.5
EBITDA Growth (3Y)(%) -4.60
XRAY's EBITDA Growth (3Y)(%) is ranked lower than
65% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. XRAY: -4.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
XRAY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -22.4  Med: 8 Max: 50.5
Current: -4.6
-22.4
50.5
EPS Growth (3Y)(%) -3.50
XRAY's EPS Growth (3Y)(%) is ranked lower than
77% of the 115 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.50 vs. XRAY: -3.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
XRAY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -32.9  Med: 9.5 Max: 88.3
Current: -3.5
-32.9
88.3
GuruFocus has detected 4 Warning Signs with Dentsply Sirona Inc $XRAY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» XRAY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

XRAY Guru Trades in Q1 2016

Columbia Wanger 890,432 sh (New)
Ruane Cunniff 4,843,324 sh (New)
Joel Greenblatt 412,656 sh (+535.07%)
Paul Tudor Jones 7,300 sh (+87.18%)
Jim Simons Sold Out
Chris Davis Sold Out
Andreas Halvorsen Sold Out
Chuck Royce 56,000 sh (-4.92%)
Mario Gabelli 130,610 sh (-10.76%)
Vanguard Health Care Fund 1,904,590 sh (-48.09%)
» More
Q2 2016

XRAY Guru Trades in Q2 2016

Ray Dalio 6,000 sh (New)
Jim Simons 182,658 sh (New)
Chuck Royce 66,000 sh (+17.86%)
Vanguard Health Care Fund 1,904,590 sh (unchged)
Joel Greenblatt Sold Out
Ruane Cunniff 4,705,249 sh (-2.85%)
Mario Gabelli 126,210 sh (-3.37%)
Columbia Wanger 768,298 sh (-13.72%)
Paul Tudor Jones 4,500 sh (-38.36%)
» More
Q3 2016

XRAY Guru Trades in Q3 2016

Andreas Halvorsen 694,607 sh (New)
Paul Tudor Jones 8,243 sh (+83.18%)
Ruane Cunniff 8,163,402 sh (+73.50%)
Chuck Royce 69,000 sh (+4.55%)
Vanguard Health Care Fund 1,904,590 sh (unchged)
Mario Gabelli 125,310 sh (-0.71%)
Jim Simons 180,458 sh (-1.20%)
Columbia Wanger 614,039 sh (-20.08%)
Ray Dalio 4,500 sh (-25.00%)
» More
Q4 2016

XRAY Guru Trades in Q4 2016

Pioneer Investments 877,100 sh (New)
Andreas Halvorsen 1,680,154 sh (+141.89%)
Jim Simons 301,858 sh (+67.27%)
Ruane Cunniff 9,102,714 sh (+11.51%)
Chuck Royce 75,900 sh (+10.00%)
Vanguard Health Care Fund 1,904,590 sh (unchged)
Ray Dalio Sold Out
Paul Tudor Jones Sold Out
Mario Gabelli 121,210 sh (-3.27%)
Columbia Wanger 516,159 sh (-15.94%)
» More
» Details

Insider Trades

Latest Guru Trades with XRAY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339114    SIC: 3843
Compare:OTCPK:CLPBY, OTCPK:TRUMY, NYSE:WAT, NYSE:MTD, NYSE:BCR, OTCPK:OCPNF, NAS:HOLX, NYSE:RMD, NYSE:COO, OTCPK:SAUHY, NYSE:WST, NYSE:STE, NAS:ILMN, OTCPK:ESLOY, NYSE:HRC, OTCPK:GNGBY, NYSE:CMD, NAS:ICUI, NAS:PODD, OTCPK:ANSLY » details
Traded in other countries:DY2.Germany,
DENTSPLY International Inc is a designer, developer, manufacturer and marketer of consumable dental products for the professional dental market. The Company also manufactures and markets other consumable medical device products.

Dentsply Sirona Inc, formerly DENTSPLY International Inc was incorporated in 1899 in Delaware. The Company is a designer, developer, manufacturer and marketer of consumable dental products for the professional dental market. The Company also manufactures and markets other consumable medical device products. The Company's main product categories are dental consumable products, dental laboratory products, dental specialty products and consumable medical device products. The Company conducted its business through four operating segments. All of the Company's segments are mainly engaged in the design, manufacture and distribution of dental and medical products in four principal product categories: dental consumable products; dental laboratory products; dental specialty products; and consumable medical device products. Dental consumable products consist of dental sundries and small equipment used in dental offices for the treatment of patients. The Company's dental sundry products in the dental consumable products category include dental anesthetics, prophylaxis paste, dental sealants, impression materials, restorative materials, tooth whiteners and topical fluoride. Dental laboratory products are used in the preparation of dental appliances by dental laboratories. The Company's products in the dental laboratory products category include dental prosthetics, including artificial teeth, precious metal dental alloys, dental ceramics and crown and bridge materials. Dental specialty products are specialized treatment products used within the dental office and laboratory settings. The Company's products in this category include endodontic (root canal) instruments and materials, implants and related products, bone grafting materials, 3D digital implantology, dental lasers and orthodontic appliances and accessories. Consumable medical device products consist mainly of urological products including catheters, certain surgical products, medical drills and other non-medical products. The Company conducts its business in the United States of America ('U.S.'), as well as in over 120 foreign countries, principally through its foreign subsidiaries. The Company has presence in the European market, particularly in Germany, Sweden, Switzerland, France, Italy and the United Kingdom as well as in Canada. The Company also has market presence in the countries of the Commonwealth of Independent States ('CIS'), Central and South America and the Pacific Rim. The Company's products are subject to regulation by, among other governmental entities, the U.S. Food and Drug Administration.

Guru Investment Theses on Dentsply Sirona Inc

Ruane Cunniff Comments on Dentsply Sirona - Oct 13, 2016

After a busy second quarter in terms of portfolio activity, the third quarter was far quieter. Our only significant purchase was of the dental supply leader Dentsply Sirona (NASDAQ:XRAY). We’ve owned predecessor company Sirona since 2011, and it has been an excellent performer. Our original investment thesis was based on Sirona’s leadership in digital dentistry. Sirona is strong in digital equipment, and its product line includes CEREC, an incredibly innovative and useful CAD/CAM system that allows dentists to design and mill crowns in their offices during the course of a single patient visit. The merger brings together the highest-tech maker of dental equipment (Sirona) with the largest maker of dental consumables (Dentsply), creating the industry’s largest global supplier. It is our belief that Dentsply Sirona is in a unique position to create and sell new value-added solutions in both equipment and consumables over the years ahead. In addition, we think CEO Jeff Slovin is the right person to drive the combined organization toward a world-class level of performance.

From Ruane Cunniff (Trades, Portfolio)'s Sequoia Fund third quarter 2016 letter to shareholders.

Check out Ruane Cunniff latest stock trades

Top Ranked Articles about Dentsply Sirona Inc

Ruane Cunniff Makes One Significant Buy Sequoia Fund enters dental space after disposing of Valeant
On Tuesday, Ruane Cunniff (Trades, Portfolio) disclosed its first quarterly update since losing significantly on a position in Valeant Pharmaceuticals (NYSE:VRX), a fast-growing drug maker accused of price gouging and a dubious relationship with a pharmacy. The firm’s Sequoia Fund made only one large purchase during the third quarter, Dentsply Sirona (NASDAQ:XRAY). Read more...
Ruane Cunniff Comments on Dentsply Sirona Guru stock highlight
After a busy second quarter in terms of portfolio activity, the third quarter was far quieter. Our only significant purchase was of the dental supply leader Dentsply Sirona (NASDAQ:XRAY). We’ve owned predecessor company Sirona since 2011, and it has been an excellent performer. Our original investment thesis was based on Sirona’s leadership in digital dentistry. Sirona is strong in digital equipment, and its product line includes CEREC, an incredibly innovative and useful CAD/CAM system that allows dentists to design and mill crowns in their offices during the course of a single patient visit. The merger brings together the highest-tech maker of dental equipment (Sirona) with the largest maker of dental consumables (Dentsply), creating the industry’s largest global supplier. It is our belief that Dentsply Sirona is in a unique position to create and sell new value-added solutions in both equipment and consumables over the years ahead. In addition, we think CEO Jeff Slovin is the right person to drive the combined organization toward a world-class level of Read more...
Ruane Cunniff Acquires Shares of Dentsply Sirona Company makes and sells products for dental market
Ruane Cunniff (Trades, Portfolio) bought a 4,843,324-share stake in Dentsply Sirona Inc. (NASDAQ:XRAY) during the first quarter. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 31.39
XRAY's P/E(ttm) is ranked lower than
58% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.87 vs. XRAY: 31.39 )
Ranked among companies with meaningful P/E(ttm) only.
XRAY' s P/E(ttm) Range Over the Past 10 Years
Min: 12.2  Med: 21.93 Max: 114
Current: 31.39
12.2
114
Forward P/E 21.32
XRAY's Forward P/E is ranked higher than
70% of the 40 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.15 vs. XRAY: 21.32 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 31.39
XRAY's PE(NRI) is ranked lower than
60% of the 115 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.49 vs. XRAY: 31.39 )
Ranked among companies with meaningful PE(NRI) only.
XRAY' s PE(NRI) Range Over the Past 10 Years
Min: 12.2  Med: 21.93 Max: 114
Current: 31.39
12.2
114
Price/Owner Earnings (ttm) 31.64
XRAY's Price/Owner Earnings (ttm) is ranked lower than
67% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.26 vs. XRAY: 31.64 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
XRAY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 12.21  Med: 20.2 Max: 104.95
Current: 31.64
12.21
104.95
P/B 1.81
XRAY's P/B is ranked higher than
73% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.45 vs. XRAY: 1.81 )
Ranked among companies with meaningful P/B only.
XRAY' s P/B Range Over the Past 10 Years
Min: 1.58  Med: 2.74 Max: 4.65
Current: 1.81
1.58
4.65
P/S 3.71
XRAY's P/S is ranked lower than
55% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.96 vs. XRAY: 3.71 )
Ranked among companies with meaningful P/S only.
XRAY' s P/S Range Over the Past 10 Years
Min: 1.59  Med: 2.41 Max: 3.72
Current: 3.71
1.59
3.72
PFCF 34.22
XRAY's PFCF is ranked lower than
60% of the 78 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.37 vs. XRAY: 34.22 )
Ranked among companies with meaningful PFCF only.
XRAY' s PFCF Range Over the Past 10 Years
Min: 12.38  Med: 19.73 Max: 34.49
Current: 34.22
12.38
34.49
POCF 26.15
XRAY's POCF is ranked lower than
67% of the 101 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.55 vs. XRAY: 26.15 )
Ranked among companies with meaningful POCF only.
XRAY' s POCF Range Over the Past 10 Years
Min: 10.45  Med: 15.35 Max: 26.51
Current: 26.15
10.45
26.51
EV-to-EBIT 33.19
XRAY's EV-to-EBIT is ranked lower than
73% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.36 vs. XRAY: 33.19 )
Ranked among companies with meaningful EV-to-EBIT only.
XRAY' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.7  Med: 18.8 Max: 59.5
Current: 33.19
9.7
59.5
EV-to-EBITDA 21.00
XRAY's EV-to-EBITDA is ranked lower than
74% of the 129 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.65 vs. XRAY: 21.00 )
Ranked among companies with meaningful EV-to-EBITDA only.
XRAY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.4  Med: 14.7 Max: 39.7
Current: 21
8.4
39.7
PEG 10.16
XRAY's PEG is ranked lower than
77% of the 56 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.03 vs. XRAY: 10.16 )
Ranked among companies with meaningful PEG only.
XRAY' s PEG Range Over the Past 10 Years
Min: 0.65  Med: 3.65 Max: 23.93
Current: 10.16
0.65
23.93
Shiller P/E 30.52
XRAY's Shiller P/E is ranked higher than
70% of the 47 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 41.26 vs. XRAY: 30.52 )
Ranked among companies with meaningful Shiller P/E only.
XRAY' s Shiller P/E Range Over the Past 10 Years
Min: 18.1  Med: 25.33 Max: 44.86
Current: 30.52
18.1
44.86
Current Ratio 2.44
XRAY's Current Ratio is ranked higher than
50% of the 176 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.39 vs. XRAY: 2.44 )
Ranked among companies with meaningful Current Ratio only.
XRAY' s Current Ratio Range Over the Past 10 Years
Min: 1.2  Med: 1.9 Max: 3.65
Current: 2.44
1.2
3.65
Quick Ratio 1.77
XRAY's Quick Ratio is ranked higher than
52% of the 176 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. XRAY: 1.77 )
Ranked among companies with meaningful Quick Ratio only.
XRAY' s Quick Ratio Range Over the Past 10 Years
Min: 0.76  Med: 1.2 Max: 2.79
Current: 1.77
0.76
2.79
Days Inventory 104.58
XRAY's Days Inventory is ranked higher than
62% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 123.69 vs. XRAY: 104.58 )
Ranked among companies with meaningful Days Inventory only.
XRAY' s Days Inventory Range Over the Past 10 Years
Min: 89.71  Med: 101.08 Max: 114.74
Current: 104.58
89.71
114.74
Days Sales Outstanding 61.98
XRAY's Days Sales Outstanding is ranked lower than
67% of the 146 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.60 vs. XRAY: 61.98 )
Ranked among companies with meaningful Days Sales Outstanding only.
XRAY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.12  Med: 56.27 Max: 61.98
Current: 61.98
53.12
61.98
Days Payable 46.87
XRAY's Days Payable is ranked higher than
53% of the 139 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 49.38 vs. XRAY: 46.87 )
Ranked among companies with meaningful Days Payable only.
XRAY' s Days Payable Range Over the Past 10 Years
Min: 31.01  Med: 36.59 Max: 46.87
Current: 46.87
31.01
46.87

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.49
XRAY's Dividend Yield is ranked lower than
84% of the 146 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.25 vs. XRAY: 0.49 )
Ranked among companies with meaningful Dividend Yield only.
XRAY' s Dividend Yield Range Over the Past 10 Years
Min: 0.35  Med: 0.54 Max: 0.85
Current: 0.49
0.35
0.85
Dividend Payout 0.16
XRAY's Dividend Payout is ranked higher than
88% of the 85 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.31 vs. XRAY: 0.16 )
Ranked among companies with meaningful Dividend Payout only.
XRAY' s Dividend Payout Range Over the Past 10 Years
Min: 0.1  Med: 0.11 Max: 0.17
Current: 0.16
0.1
0.17
Dividend Growth (3y) 7.40
XRAY's Dividend Growth (3y) is ranked lower than
59% of the 63 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.20 vs. XRAY: 7.40 )
Ranked among companies with meaningful Dividend Growth (3y) only.
XRAY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 3.2  Med: 8.9 Max: 14.8
Current: 7.4
3.2
14.8
Forward Dividend Yield 0.49
XRAY's Forward Dividend Yield is ranked lower than
87% of the 138 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.37 vs. XRAY: 0.49 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.75
XRAY's Yield on cost (5-Year) is ranked lower than
80% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.99 vs. XRAY: 0.75 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
XRAY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.53  Med: 0.82 Max: 1.3
Current: 0.75
0.53
1.3
3-Year Average Share Buyback Ratio -15.90
XRAY's 3-Year Average Share Buyback Ratio is ranked higher than
87% of the 117 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.80 vs. XRAY: -15.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
XRAY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -15.9  Med: 0.5 Max: 2.2
Current: -15.9
-15.9
2.2

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.46
XRAY's Price/Projected FCF is ranked higher than
70% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.03 vs. XRAY: 1.46 )
Ranked among companies with meaningful Price/Projected FCF only.
XRAY' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.08  Med: 1.34 Max: 2.1
Current: 1.46
1.08
2.1
Price/Median PS Value 1.53
XRAY's Price/Median PS Value is ranked lower than
76% of the 164 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. XRAY: 1.53 )
Ranked among companies with meaningful Price/Median PS Value only.
XRAY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.62  Med: 0.97 Max: 1.54
Current: 1.53
0.62
1.54
Earnings Yield (Greenblatt) (%) 3.00
XRAY's Earnings Yield (Greenblatt) (%) is ranked higher than
57% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.80 vs. XRAY: 3.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
XRAY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.7  Med: 5.3 Max: 10.3
Current: 3
1.7
10.3
Forward Rate of Return (Yacktman) (%) 6.82
XRAY's Forward Rate of Return (Yacktman) (%) is ranked lower than
53% of the 87 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.86 vs. XRAY: 6.82 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
XRAY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -3.5  Med: 9.8 Max: 31.1
Current: 6.82
-3.5
31.1

More Statistics

Revenue (TTM) (Mil) $3,745
EPS (TTM) $ 1.99
Beta1.29
Short Percentage of Float3.51%
52-Week Range $55.00 - 65.83
Shares Outstanding (Mil)230.88

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 4,102 4,319
EPS ($) 2.94 3.23
EPS w/o NRI ($) 2.94 3.23
EPS Growth Rate
(3Y to 5Y Estimate)
10.12%
Dividends Per Share ($) 0.30 0.32
» More Articles for XRAY

Headlines

Articles On GuruFocus.com
Ruane Cunniff Makes One Significant Buy Oct 14 2016 
Ruane Cunniff Comments on Dentsply Sirona Oct 13 2016 
Sequoia Fund 3rd Quarter Update, Wells Fargo an 'Attractive Franchise' Oct 13 2016 
Ruane Cunniff Acquires Shares of Dentsply Sirona Jun 23 2016 
DENTSPLY´s Growth Opportunities Dec 16 2014 
Weekly Insider Sells Highlight: ORCL, ALXN, WAT, XRAY Dec 08 2014 
Why I Like These Two Health Care Stocks Aug 29 2014 
Global for Resilience – Columbia Management Selling Update Aug 29 2013 
New Guru Added: Ray Dalio of Bridgewater Associates Dec 02 2011 
DENTSPLY International Inc. Reports Operating Results (10-K) Feb 18 2011 

More From Other Websites
DENTSPLY SIRONA, Inc. :XRAY-US: Earnings Analysis: Q4, 2016 By the Numbers : February 21, 2017 Feb 21 2017
Dentsply Sirona downgraded by Barrington Research Feb 21 2017
6:30 am Dentsply Sirona raises quarterly dividend to $0.875/share from $0.775/share Feb 20 2017
As Trump and Trudeau Tout Women's Council, Here's Who Is and Isn't Doing a Good Job at Diversity Feb 19 2017
Edited Transcript of XRAY earnings conference call or presentation 17-Feb-17 2:30pm GMT Feb 17 2017
DENTSPLY (XRAY) Beats on Earnings in Q4, Misses Revenues Feb 17 2017
Dentsply Sirona Inc Earnings Call scheduled for 9:30 am ET today Feb 17 2017
DENTSPLY (XRAY) Q4 Earnings Top Estimates, Sales Up Y/Y Feb 17 2017
DENTSPLY SIRONA INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 17 2017
Q4 2016 Dentsply Sirona Inc Earnings Release - Before Market Open Feb 17 2017
Dentsply tops 4Q profit forecasts Feb 17 2017
Dentsply tops 4Q profit forecasts Feb 17 2017
Dentsply Sirona Reports Fourth Quarter and Full Year 2016 Results Feb 17 2017
Dentsply Sirona Raises Quarterly Cash Dividend Feb 17 2017
Dentsply Sirona to Report Fourth Quarter and Fiscal 2016 Results on February 17 Feb 10 2017
DENTSPLY SIRONA INC. Files SEC form 8-K, Change in Directors or Principal Officers Feb 10 2017
DENTSPLY (XRAY) Q4 Earnings: Is Disappointment in Store? Feb 08 2017
Coty Says It Will Add First Woman Board Member by July Feb 07 2017
DENTSPLY SIRONA, Inc. breached its 50 day moving average in a Bearish Manner : XRAY-US : December... Dec 23 2016
Dentsply Sirona Declares Quarterly Cash Dividend Dec 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)